Company Overview - Avanos Medical, Inc. is a medical technology company focused on delivering clinically superior medical device solutions to help patients return to their daily activities [2] - The company is headquartered in Alpharetta, Georgia, and is committed to addressing significant healthcare needs, including providing nutrition support for patients transitioning from hospital to home and reducing opioid use during recovery [2] - Avanos develops, manufactures, and markets recognized brands globally, holding leading market positions across multiple categories in its portfolio [2] Upcoming Event - Dave Pacitti, the CEO of Avanos Medical, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13 at approximately 2:15 p.m. PST [1] - A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived for future access [1]

As filed with the Securities and Exchange Commission on January 7, 2026. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 AETHLON MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 3826 13-3632859 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 11555 Sorr ...

Core Insights - West Pharmaceutical Services, Inc. (NYSE:WST) is recognized as one of the 14 Best Dividend Growth Stocks to Buy and Hold in 2026 [1] Group 1: Market Demand and Growth Drivers - KeyBanc projects that injectable GLP-1 drugs will continue to drive demand for West Pharmaceutical, with limited risk to oral weight loss drugs through 2030 [2] - The firm estimates that the oral version of Wegovy will only contribute approximately 200 basis points to the total GLP-1 market share by 2030, indicating a conservative outlook on oral drug adoption [2] - West Pharmaceutical's drug components business now accounts for 47% of total revenue, reflecting strong demand for components used in GLP-1 weight-loss and diabetes drugs [3] Group 2: Product Offerings - West Pharmaceutical supplies essential medical components such as stoppers, plungers, and delivery systems, which are critical for the safe storage and administration of injectable medicines, including vaccines and biologics [4]

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying the right ones can be challenging due to associated risks and volatility [1] Group 1: Company Overview - Penumbra (PEN) is recommended as a cutting-edge growth stock based on its favorable Growth Score and top Zacks Rank [2] - The company has a historical EPS growth rate of 78.6%, with a projected EPS growth of 35.1% this year, significantly outperforming the industry average of 11.4% [4] Group 2: Financial Metrics - Year-over-year cash flow growth for Penumbra is currently at 1.5%, exceeding the industry average of -2.4% [5] - The annualized cash flow growth rate over the past 3-5 years is 20.5%, compared to the industry average of 6.3% [6] Group 3: Earnings Estimates - There has been a positive trend in earnings estimate revisions for Penumbra, with the Zacks Consensus Estimate for the current year increasing by 0.3% over the past month [7] - The combination of a Zacks Rank 2 and a Growth Score of A positions Penumbra favorably for potential outperformance [9]

Core Insights - Butterfly Network (BFLY) plans to launch its Beam Steering API in the first half of 2026, enabling third-party developers to access advanced imaging capabilities previously exclusive to BFLY's applications [1][6] - The API will enhance imaging AI tools and simplify image capture, utilizing software-based beam steering on a semiconductor chip [2][8] - Following the announcement, BFLY shares increased by 4.9%, marking a 115.9% rise over the past six months, while the industry saw a decline of 0.7% [3][6] Company Developments - The Beam Steering API will allow developers to leverage BFLY's 3D imaging capabilities, fostering innovation and expanding ultrasound applications across various healthcare settings [4][9] - BFLY's current market capitalization stands at $977.57 million [4] - The technology is based on a semiconductor chip with approximately 9,000 elements, allowing for software-controlled ultrasound beams and improved imaging precision [8] Industry Context - The AI in ultrasound imaging market is projected to reach $1.12 billion by 2025, with a CAGR of 8.45% through 2034, driven by the increasing recognition of AI benefits in diagnostics [10] - The demand for AI-assisted workflows is critical as portable ultrasound technology becomes more prevalent in diverse clinical environments [9]

Core Insights - AngioDynamics, Inc. (ANGO) reported breakeven adjusted earnings per share for the second quarter of fiscal 2026, an improvement from a loss of 4 cents in the same quarter last year, surpassing the Zacks Consensus Estimate of a loss of 10 cents [1][2] - The company’s pro-forma revenues for the fiscal second quarter reached $79.4 million, reflecting an 8.8% year-over-year increase and exceeding the Zacks Consensus Estimate by 4.5% [3][10] - Despite the positive financial results, shares of AngioDynamics fell nearly 13.5% in the trading session following the announcement [4] Revenue Analysis - U.S. net revenues for the quarter totaled $67.6 million, up 7.8% year over year, surpassing the estimate of $62.3 million [5] - Pro-forma international revenues were $11.8 million, an 8.8% increase from the previous year, exceeding the projection of $10.2 million [5] Segment Performance - The Med Tech segment reported pro-forma net sales of $35.7 million, a 13% increase year over year, outperforming the estimate of $32.7 million [6] - Key drivers included Auryon sales of $16.3 million (up 18.6% year over year) and Mechanical Thrombectomy revenues of $11 million (up 3.9% year over year) [7] - Pro-forma Med Device revenues totaled $43.8 million, reflecting a 5.6% increase compared to the previous year, also exceeding the estimate of $39.9 million [8] Margin and Expense Analysis - AngioDynamics' pro forma gross profit rose 14% to $44.8 million, with gross margin expanding by 170 basis points to 56.4%, surpassing the projected margin of 54.2% [11][10] - Sales and marketing expenses increased by 4.4% year over year to $26.7 million, while R&D expenses rose by 20.7% to $7.8 million [12] Cash Position - The company ended the second quarter with cash and cash equivalents of $41.6 million, up from $38.8 million at the end of the previous quarter, with no debt on its balance sheet [13] Fiscal Year Guidance - AngioDynamics updated its fiscal 2026 sales guidance to a range of $312-$314 million, up from the previous guidance of $308-$313 million [14] - The company anticipates Med Tech revenue growth of 14-16% and flat to 1% growth for Med Device revenues [15] - Adjusted loss per share is projected to be between 33 cents and 23 cents, with the Zacks Consensus Estimate at a loss of 28 cents per share [16] Overall Assessment - AngioDynamics demonstrated strong execution in the second quarter, with revenue growth driven by the higher-margin Med Tech portfolio, which now accounts for 45% of total revenue [17] - Auryon continues to be a significant growth driver, achieving its 18th consecutive quarter of double-digit growth [18] - The Mechanical Thrombectomy segment showed mid-single-digit growth, with regulatory advancements expected to enhance adoption and clinical use [19]

Core Insights - Intuitive Surgical (ISRG) stock has increased by 32.4% over the past three months, currently trading at $592.85, just 3.8% below its all-time high of $616 reached in February 2025, reflecting strong investor confidence following robust third-quarter earnings [1][19] Financial Performance - ISRG has outperformed peers like Medtronic (MDT) and PROCEPT BioRobotics (PRCT) in the past three months, with MDT gaining 2.5% and PRCT declining by 0.1% [2] - Total worldwide procedures grew by 20% year over year, driven by a 19% increase in da Vinci procedures and a 52% increase in Ion procedures [2][7] Growth Drivers - Procedure growth is a key component of Intuitive Surgical's long-term value creation, with strong performance noted across various geographies and specialties, including U.S. benign general surgery and international growth in general surgery, gynecology, colorectal, and thoracic procedures [3] - Average system utilization increased by 4% for da Vinci multiport, 35% for SP, and 14% for Ion, indicating rising throughput within the installed base [4] Product Development - The launch of da Vinci 5 is a significant catalyst for revenue growth, with 240 systems placed in Q3, bringing the global installed base to 929 systems [5][7] - Approximately 85% of ISRG's revenues come from recurring sales, supported by features and upgrades of da Vinci 5 [7][9] Competitive Landscape - Rising competition in surgical robotics includes Medtronic's Hugo platform and Procept BioRobotics' AI-powered HYDROS system, which could impact Intuitive Surgical's market dominance [14][16] Future Outlook - Estimates for Intuitive Surgical's 2025 earnings have increased by 8.5% to $8.65 per share, indicating bullish sentiment [17] - Sustained procedure growth, rising utilization, and accelerating da Vinci 5 adoption position the company for durable growth into 2026 [20]

Philadelphia, Pennsylvania--(Newsfile Corp. - January 7, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) ("Integer" or the "Company") on behalf of investors who purchased or otherwise acquired Integer securities during the period of July 25, 2024 through October 22, 2025 (the "Class Period"), inclusive.Investor Deadline: Investors who purchased Integer securities during the Class Period may, no l ...

Company Overview - Align Technology, Inc. (ALGN) has a market capitalization of $11.2 billion and specializes in developing and providing Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services globally [1] Financial Performance - The company is expected to announce its fiscal Q4 2025 results on February 4, with analysts predicting earnings of $2.47 per share, reflecting a 26% increase from $1.96 per share in the same quarter last year [2] - For fiscal 2025, analysts forecast an EPS of $8.18, which represents a 16.7% increase from $7.01 in fiscal 2024 [3] - Following the Q3 2025 results on October 29, ALGN shares rose by 4.9%, with adjusted EPS reported at $2.61 and revenue at $995.7 million, surpassing consensus estimates [5] Market Performance - Over the past 52 weeks, ALGN stock has declined by 22.5%, underperforming the S&P 500 Index, which rose by 16.2%, and the State Street Health Care Select Sector SPDR ETF, which returned 13.3% [4] Analyst Sentiment - The consensus rating for ALGN stock is "Moderate Buy," with 15 analysts providing coverage: eight rated it as "Strong Buy," six as "Hold," and one as "Moderate Sell" [6] - The average analyst price target for ALGN is $171.38, indicating a potential upside of 2.2% from current levels [6]

Core Insights - The article emphasizes the importance of efficiency levels in assessing a company's potential for profit generation, with a high efficiency level correlating positively with price performance [1] Efficiency Ratios - The article identifies key efficiency ratios for stock selection, including Receivables Turnover, Asset Utilization, Inventory Turnover, and Operating Margin, which help gauge a company's ability to manage credit, assets, inventory, and operating expenses effectively [2][3][4][5] - A favorable Zacks Rank (1 Strong Buy) is also included as a criterion to enhance the profitability of the stock screening process [6] Stock Screening Results - The screening process narrowed down over 7,906 stocks to 16, highlighting five companies that excel in efficiency ratios compared to industry averages [7] - The top five stocks identified are: - **United Natural Foods (UNFI)**: A leading distributor with a 52.10% average four-quarter earnings surprise [8][9] - **Northrim BanCorp (NRIM)**: A full-service commercial bank with a 19% average four-quarter earnings surprise [10] - **Lightspeed POS (LSPD)**: A commerce platform provider with a 17.9% average four-quarter earnings surprise [11] - **Ulta Beauty (ULTA)**: A prominent beauty retailer with a 15.7% average four-quarter earnings surprise [12] - **Electromed (ELMD)**: A manufacturer of airway clearance therapy products with a 13.6% average four-quarter earnings surprise [13]